Curasight on the agreement with Curium
Copenhagen-based Curasight has worked tirelessly to secure a partnership deal for uTRACE. Now, the company finally announces that it has reached a deal with global radiopharmaceuticals specialist Curium, regarding the diagnosis of prostate cancer patients. The agreement include milestone payments of up to 70 MUSD, plus double-digit royalties on future sales. BioStock invited CEO Ulrich Krasilnikoff and Chief Scientific Officer Andreas Kjaer to the studio to learn more about what this means for the company.
Watch the interview with Curasight’s CEO Ulrich Krasilnikoff and Head of Research Andreas Kjaer below.
